# Rapamycin Shows Potential to Protect Brains at Risk of Alzheimer's An existing transplant drug improves brain blood flow in middle-aged APOE4 gene carriers. - **Source:** [ScienceDaily – Top](https://www.sciencedaily.com) - **Published:** 2026-11-06 - **Topic:** [health](https://brifing.si/c/health) - **Original article:** - **On Brifing:** https://brifing.si/s/6a0d8398-f475-4ec7-af41-c51f585be111 ## Repurposing Transplant Medication Researchers at the University of Missouri are investigating rapamycin, a drug typically used to prevent organ transplant rejection, for its potential to combat Alzheimer's disease. The study focuses on middle-aged adults, specifically those carrying the APOE4 gene variant, which is known to significantly increase the risk of developing dementia later in life. ## Targeting Early Warning Signs The research centers on the observation that APOE4 carriers often experience reduced cerebral blood flow years before memory issues manifest. By improving circulation in these specific brain regions, scientists hope to intervene early in the disease process, potentially delaying or reducing the overall risk of Alzheimer's development in vulnerable individuals. ## Experimental Methodology and Results The pilot trial involved healthy participants aged 45 to 65 who received a low daily dose of rapamycin for four weeks. Results indicated that brain blood flow improved specifically among those carrying the APOE4 gene variant, while participants without the variant did not experience the same physiological benefits from the treatment. ## Gender-Specific Treatment Outcomes A notable finding from the study was that women carrying the APOE4 gene experienced the most significant improvements in brain blood flow. This discovery is particularly relevant because women currently account for nearly two-thirds of the global population living with Alzheimer's disease, highlighting the importance of gender-specific medical research approaches. ## Advancing Precision Medicine This study exemplifies the principles of precision medicine, which tailors treatments based on individual genetic profiles rather than applying a universal standard. By identifying that only specific genetic carriers benefit from rapamycin, researchers are moving toward more targeted therapeutic strategies that could eventually improve long-term brain health outcomes for high-risk groups. ## Collaborative Research Environment The study was conducted at the Roy Blunt NextGen Precision Health building, a facility designed to foster collaboration between scientists and medical professionals. This environment accelerates the transition of laboratory findings into human clinical trials, allowing for faster evaluation of potential treatments like rapamycin for complex, age-related neurological conditions. ## Historical Context and Precedents Before human trials, lead investigator Ai-Ling Lin conducted experiments on mice carrying the APOE4 gene. These earlier studies demonstrated that rapamycin could effectively slow brain aging and enhance cerebral blood flow in animal models, providing the necessary scientific foundation to test whether similar benefits could be replicated in human subjects. ## Future Clinical Implications While the current findings are encouraging, further research is required to determine if these improvements in blood flow lead to lasting cognitive preservation. Scientists must now conduct larger, long-term studies to confirm whether rapamycin can definitively lower the likelihood of Alzheimer's disease or effectively delay the onset of memory-related symptoms. ## Sources covering this story - https://www.sciencedaily.com/releases/2026/11/261104084017.htm — --- _Summary written by Brifing from the original reporting. Copyright in the original article belongs to its publisher; read the full piece at the link above._